Literature DB >> 10918871

The fluoroquinolones.

R C Walker1.   

Abstract

The quinolones are broad-spectrum antibacterial agents that have a novel mechanism of action. As synthetic compounds, these agents have been developed extensively to optimize antimicrobial activity, pharmacokinetic properties, and drug safety. Although earlier quinolones were effective only in the genitourinary and gastrointestinal tracts and only had activity against aerobic gram-negative bacteria, newer quinolones have wider potential applications and a broader spectrum of activity. Some of the newer quinolones will have a role in the treatment of community-acquired pneumonia and intra-abdominal infections. Ciprofloxacin remains the most potent quinolone against Pseudomonas aeruginosa. Among the quinolones, important differences exist in renal and hepatic elimination and dose-adjustment regimens. Although there are many Food and Drug Administration-approved indications for some of the newer quinolones, the quinolones are the drug of choice for only a few infections. Quinolone-resistant bacteria are being increasingly identified and emerge under selective pressure created by extensive use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10918871     DOI: 10.4065/74.10.1030

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  17 in total

Review 1.  Formulations of antibiotics for children in primary care: effects on compliance and efficacy.

Authors:  Andres Ramgoolam; Russell Steele
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.

Authors:  J H Jorgensen; L M Weigel; J M Swenson; C G Whitney; M J Ferraro; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

3.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

4.  Prevention of febrile neutropenia: use of prophylactic antibiotics.

Authors:  M Cullen; S Baijal
Journal:  Br J Cancer       Date:  2009-09       Impact factor: 7.640

5.  An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous.

Authors:  M Hui; A K H Kwok; C P Pang; S W Cheung; R C Y Chan; D S C Lam; A F B Cheng
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

6.  Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.

Authors:  D E Karageorgopoulos; S Maraki; A C Vatopoulos; G Samonis; G C Schito; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-19       Impact factor: 3.267

7.  A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.

Authors:  P Patrick Basu; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Nithya Krishnaswamy; Molly Flynn
Journal:  Am J Gastroenterol       Date:  2011-10-11       Impact factor: 10.864

8.  Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells.

Authors:  Sujan Badal; Yeng F Her; L James Maher
Journal:  J Biol Chem       Date:  2015-07-23       Impact factor: 5.157

9.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28

10.  In vitro activity of levofloxacin against lower respiratory tract pathogens.

Authors:  Soma Sarkar; Atreyi Chakraborty; Mallika Sengupta; Sougata Ghosh; Subhasish Mukhopadhyay; Manideepa SenGupta
Journal:  J Basic Clin Pharm       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.